![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Fast-Track Designation for Phenoxodiol in Oral Dosage Form
FDA Grants Fast-Track Designation for Phenoxodiol in Oral Dosage Form
The FDA has granted Marshall Edwards' investigational anticancer drug, phenoxodiol, fast-track status for its intended use in patients with hormone-refractory prostate cancer (HRPC).
The successful application for fast-track status was based on data derived in a Phase Ib/IIa study, conducted in two Australian hospitals, in which men with late stage HRPC were treated with the oral dosage form of phenoxodiol as a monotherapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct